Hong Kong Cancer Drug Co. Snags $100M Equity Investment
A Hong Kong-based cancer and autoimmune disease drug company said Thursday that it has received a $100 million equity investment from growth equity firm General Atlantic to fund drug research and...To view the full article, register now.
Already a subscriber? Click here to view full article